Cargando…
Screening for non-adherence to antihypertensive treatment as a part of the diagnostic pathway to renal denervation
Renal denervation is a potential therapeutic option for resistant hypertension. A thorough clinical assessment to exclude reversible/spurious causes of resistance to antihypertensive therapy is required prior to this procedure. The extent to which non-adherence to antihypertensive treatment contribu...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4856755/ https://www.ncbi.nlm.nih.gov/pubmed/26446393 http://dx.doi.org/10.1038/jhh.2015.103 |
_version_ | 1782430536221851648 |
---|---|
author | Patel, P Gupta, P K C White, C M J Stanley, A G Williams, B Tomaszewski, M |
author_facet | Patel, P Gupta, P K C White, C M J Stanley, A G Williams, B Tomaszewski, M |
author_sort | Patel, P |
collection | PubMed |
description | Renal denervation is a potential therapeutic option for resistant hypertension. A thorough clinical assessment to exclude reversible/spurious causes of resistance to antihypertensive therapy is required prior to this procedure. The extent to which non-adherence to antihypertensive treatment contributes to apparent resistance to antihypertensive therapy in patients considered for renal denervation is not known. Patients (n=34) referred for renal denervation entered the evaluation pathway that included screening for adherence to antihypertensive treatment by high-performance liquid chromatography-tandem mass spectrometry-based urine analysis. Biochemical non-adherence to antihypertensive treatment was the most common cause of non-eligibility for renal denervation—23.5% of patients were either partially or completely non-adherent to prescribed antihypertensive treatment. About 5.9% of those referred for renal denervation had admitted non-adherence prior to performing the screening test. Suboptimal pharmacological treatment of hypertension and ‘white-coat effect' accounted for apparently resistant hypertension in a further 17.7 and 5.9% of patients, respectively. Taken together, these three causes of pseudo-resistant hypertension accounted for 52.9% of patients referred for renal denervation. Only 14.7% of referred patients were ultimately deemed eligible for renal denervation. Without biochemical screening for therapeutic non-adherence, the eligibility rate for renal denervation would have been 38.2%. Non-adherence to antihypertensive treatment and other forms of therapeutic pseudo-resistance are by far the most common reason of ‘resistant hypertension' in patients referred for renal denervation. We suggest that inclusion of biochemical screening for non-adherence to antihypertensive treatment may be helpful in evaluation of patients with ‘resistant hypertension' prior to consideration of renal denervation. |
format | Online Article Text |
id | pubmed-4856755 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-48567552016-05-23 Screening for non-adherence to antihypertensive treatment as a part of the diagnostic pathway to renal denervation Patel, P Gupta, P K C White, C M J Stanley, A G Williams, B Tomaszewski, M J Hum Hypertens Original Article Renal denervation is a potential therapeutic option for resistant hypertension. A thorough clinical assessment to exclude reversible/spurious causes of resistance to antihypertensive therapy is required prior to this procedure. The extent to which non-adherence to antihypertensive treatment contributes to apparent resistance to antihypertensive therapy in patients considered for renal denervation is not known. Patients (n=34) referred for renal denervation entered the evaluation pathway that included screening for adherence to antihypertensive treatment by high-performance liquid chromatography-tandem mass spectrometry-based urine analysis. Biochemical non-adherence to antihypertensive treatment was the most common cause of non-eligibility for renal denervation—23.5% of patients were either partially or completely non-adherent to prescribed antihypertensive treatment. About 5.9% of those referred for renal denervation had admitted non-adherence prior to performing the screening test. Suboptimal pharmacological treatment of hypertension and ‘white-coat effect' accounted for apparently resistant hypertension in a further 17.7 and 5.9% of patients, respectively. Taken together, these three causes of pseudo-resistant hypertension accounted for 52.9% of patients referred for renal denervation. Only 14.7% of referred patients were ultimately deemed eligible for renal denervation. Without biochemical screening for therapeutic non-adherence, the eligibility rate for renal denervation would have been 38.2%. Non-adherence to antihypertensive treatment and other forms of therapeutic pseudo-resistance are by far the most common reason of ‘resistant hypertension' in patients referred for renal denervation. We suggest that inclusion of biochemical screening for non-adherence to antihypertensive treatment may be helpful in evaluation of patients with ‘resistant hypertension' prior to consideration of renal denervation. Nature Publishing Group 2016-06 2015-10-08 /pmc/articles/PMC4856755/ /pubmed/26446393 http://dx.doi.org/10.1038/jhh.2015.103 Text en Copyright © 2016 Macmillan Publishers Limited http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Original Article Patel, P Gupta, P K C White, C M J Stanley, A G Williams, B Tomaszewski, M Screening for non-adherence to antihypertensive treatment as a part of the diagnostic pathway to renal denervation |
title | Screening for non-adherence to antihypertensive treatment as a part of the diagnostic pathway to renal denervation |
title_full | Screening for non-adherence to antihypertensive treatment as a part of the diagnostic pathway to renal denervation |
title_fullStr | Screening for non-adherence to antihypertensive treatment as a part of the diagnostic pathway to renal denervation |
title_full_unstemmed | Screening for non-adherence to antihypertensive treatment as a part of the diagnostic pathway to renal denervation |
title_short | Screening for non-adherence to antihypertensive treatment as a part of the diagnostic pathway to renal denervation |
title_sort | screening for non-adherence to antihypertensive treatment as a part of the diagnostic pathway to renal denervation |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4856755/ https://www.ncbi.nlm.nih.gov/pubmed/26446393 http://dx.doi.org/10.1038/jhh.2015.103 |
work_keys_str_mv | AT patelp screeningfornonadherencetoantihypertensivetreatmentasapartofthediagnosticpathwaytorenaldenervation AT guptapkc screeningfornonadherencetoantihypertensivetreatmentasapartofthediagnosticpathwaytorenaldenervation AT whitecmj screeningfornonadherencetoantihypertensivetreatmentasapartofthediagnosticpathwaytorenaldenervation AT stanleyag screeningfornonadherencetoantihypertensivetreatmentasapartofthediagnosticpathwaytorenaldenervation AT williamsb screeningfornonadherencetoantihypertensivetreatmentasapartofthediagnosticpathwaytorenaldenervation AT tomaszewskim screeningfornonadherencetoantihypertensivetreatmentasapartofthediagnosticpathwaytorenaldenervation |